Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial
Taylor JH, Landeros-Weisenberger A, Coughlin C, Mulqueen J, Johnson JA, Gabriel D, Reed MO, Jakubovski E, Bloch MH. Ketamine for Social Anxiety Disorder: A Randomized, Placebo-Controlled Crossover Trial. Neuropsychopharmacology 2017, 43: 325-333. PMID: 28849779, PMCID: PMC5729569, DOI: 10.1038/npp.2017.194.Peer-Reviewed Original ResearchConceptsLiebowitz Social Anxiety ScaleSocial anxiety disorderAnxiety disordersSocial Anxiety ScaleSelf-reported anxietySocial phobia symptomsRatings of anxietyPotent N-methyl-d-aspartate receptor antagonistPhobia symptomsAnxiety symptomsAnxiety ScaleImpact of ketamineInitial evidenceAnxietyTreatment respondersVAS anxietyPlacebo-controlled crossover trialRatingsDisordersLinear mixed modelsPrior studiesConcept trialInadequate symptom reliefRandom orderMixed modelsThe efficacy of benzodiazepines as acute anxiolytics in children: A meta‐analysis
Kuang H, Johnson JA, Mulqueen JM, Bloch MH. The efficacy of benzodiazepines as acute anxiolytics in children: A meta‐analysis. Depression And Anxiety 2017, 34: 888-896. PMID: 28504861, PMCID: PMC5629100, DOI: 10.1002/da.22643.Peer-Reviewed Original ResearchConceptsEfficacy of benzodiazepinesPediatric patientsAnxiety disordersTolerability of benzodiazepinesRoom proceduresCurrent practice guidelinesStandardized mean differenceFunnel plot asymmetryOperating room proceduresProcedural settingsPediatric anxiety disordersTolerability analysisAcute managementBenzodiazepine treatmentStratified subgroupsPractice guidelinesControl groupAcute anxiolyticPublication biasAnxiolyticsBenzodiazepinesMean differencePatientsSpecific agentsAnxiety levels